Theriva Biologics logo

Theriva BiologicsNYSE: TOVX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 December 2006

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.52 M
-97%vs. 3y high
4%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 25 Oct 2024 23:10:58 GMT
$1.51-$0.02(-1.31%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TOVX Latest News

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
globenewswire.com16 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program
globenewswire.com16 September 2024 Sentiment: POSITIVE

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies

Theriva Biologics Announces Reverse Stock Split
globenewswire.com16 August 2024 Sentiment: NEUTRAL

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company's common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The reverse stock split was authorized by the Company's Board of Directors on August 15, 2024. Pursuant to the laws of the State of Nevada, the Company's state of incorporation, the Company's Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company's common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
globenewswire.com31 July 2024 Sentiment: POSITIVE

ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva's lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
GlobeNewsWire19 March 2024 Sentiment: POSITIVE

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 25, 2024, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2023 and provide a corporate update.

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript
Seeking Alpha17 November 2023 Sentiment: POSITIVE

Theriva Biologics, Inc. (NYSE:TOVX ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Steve Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director, European Subsidiary Dr. Vince Wacher - Head, Corporate and Product Development Conference Call Participants James Molloy - Alliance Global Partners Operator Greetings, and welcome to the Theriva Biologics, Inc. 2023 Third Quarter Operational Highlights and Financial Results. [Operator Instructions] As a reminder, this conference is being recorded.

Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript
Seeking Alpha12 August 2023 Sentiment: POSITIVE

Theriva Biologics, Inc. (NYSE:TOVX ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Chris Calabrese - IR, LifeSci Advisors Steven Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director Dr. Vince Wacher - Head, Corporate and Product Development Conference Call Participants James Molloy - Alliance Global Partners Operator Ladies and gentlemen, good morning, and welcome to the Theriva Biologics, Inc. 2023 Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Theriva Biologics jumps on US FDA approval for pancreatic cancer treatment
Proactive Investors28 June 2023 Sentiment: POSITIVE

Theriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. VCN-01 is a selective, stroma-degrading oncolytic adenovirus being evaluated in combination with standard-of-care chemotherapy as a first-line therapy for patients with pancreatic ductal adenocarcinoma (PDAC) in the ongoing VIRAGE Phase 2b clinical study.

What type of business is Theriva Biologics?

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

What sector is Theriva Biologics in?

Theriva Biologics is in the Healthcare sector

What industry is Theriva Biologics in?

Theriva Biologics is in the Biotechnology industry

What country is Theriva Biologics from?

Theriva Biologics is headquartered in United States

When did Theriva Biologics go public?

Theriva Biologics initial public offering (IPO) was on 18 December 2006

What is Theriva Biologics website?

https://therivabio.com

Is Theriva Biologics in the S&P 500?

No, Theriva Biologics is not included in the S&P 500 index

Is Theriva Biologics in the NASDAQ 100?

No, Theriva Biologics is not included in the NASDAQ 100 index

Is Theriva Biologics in the Dow Jones?

No, Theriva Biologics is not included in the Dow Jones index

When was Theriva Biologics the previous earnings report?

No data

When does Theriva Biologics earnings report?

The next expected earnings date for Theriva Biologics is 13 November 2024